Wnt5a/Ror2信号通过BCR-ABL和中心体上β-catenin抑制CML细胞增殖机制研究

基本信息
批准号:81370624
项目类别:面上项目
资助金额:70.00
负责人:司维柯
学科分类:
依托单位:中国人民解放军第三军医大学
批准年份:2013
结题年份:2017
起止时间:2014-01-01 - 2017-12-31
项目状态: 已结题
项目参与者:张诚,刘涛,张晓丽,潘静,牛长春,李志强,赵宸,吴韦铷
关键词:
慢性粒细胞白血病Wnt5aBCRABL中心体βcatenin
结项摘要

Wnt5a is a leukemia suppressor, but the mechanism was unknown. Our previous study showed that Wnt5a/Ror2 signal inhibited β-catenin and suppressed the proliferation of CML (Chronic Myelogenous Leukemia)cell line K562 .But whether Wnt5a also regulates "BCR-ABL",the oncogene of CML? Besides we found that Wnt5a/Ror2 seem located in the site of centrosome,and β-catenin is relative to the separation of centrosome .Dose Wnt5a also regulate the separation of centrosome through β-catenin ? All of these remains unknown.This project attempts to verify the following hypothesis by research: 1.Wnt5a/Ror2 inhibits the function of BCR-ABL and downregulats the activity of β-catenin,and then suppresses the proliferation of CML cells and enhances the efficacy of Imatinib killing CML cells.2.Wnt5a/Ror2 blocks centrosome separation and mitosis progress and then play antitumor effect by regulating β-catenin on centrosome. The study result is helpful to further understand the double mechanism of Wnt5a anti-leukemia by regulating both of β-catenin and BCR-ABL, and provides a new perspective for the therapy of leukemia. Furthermore the study result will enriching the correlation theory of the relationship between Wnt signaling and tumorigenesis.

Wnt5a是白血病抑制因子,但确切机制不明。我们前期研究发现:CML细胞K562中Wnt5a/Ror2信号抑制β-catenin,阻止细胞恶性增殖。但Wnt5a是否也调控了CML 的特异癌基因"BCR-ABL"?另外还发现Wnt5a/Ror2定位于似中心体位置,而β-catenin与中心体分离有关,那么Wnt5a是否通过β-catenin调控中心体的分离?这些问题至今未见报道。本项目通过研究拟验证如下假设:1.Wnt5a/Ror2可拮抗BCR-ABL功能,进而下调β-catenin活性,抑制CML细胞增殖并增强抗CML药-伊马替尼的效力。2.Wnt5a/Ror2通过调控中心体上β-catenin,阻滞中心体分离和有丝分裂进程,发挥抑癌作用。研究结果有助于深入认识Wnt5a调控β-catenin和BCR-ABL抗白血病"双重"机制,为CML治疗提供新思路,并丰富Wnt信号与肿瘤发生相关理论。

项目摘要

Wnt5a是白血病抑制因子,CML细胞K562中Wnt5a/Ror2信号不但抑制β-catenin,阻止细胞恶性增殖,而且Wnt5a也调控了CML 的特异癌基因“BCR-ABL”,另外还发现Wnt5a/Ror2定位于似中心体位置,而β-catenin与中心体分离有关,研究发现:Wnt5a也通过β-catenin调控了中心体的分离。本项目通过研究验证了如下假设:1.Wnt5a/Ror2可拮抗BCR-ABL功能,进而下调β-catenin活性,抑制CML细胞增殖并增强伊马替尼杀灭白血病细胞的药效。2.Wnt5a/Ror2通过调控中心体上β-catenin,阻滞中心体分离和有丝分裂进程,发挥抑癌作用。研究结果有助于深入认识Wnt5a调控β-catenin和BCR-ABL抗白血病的双重机制,并丰富了Wnt信号与肿瘤发生相关理论,也为CML治疗提供了新思路,为诊断CML提供了新靶标。

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

Mechanical vibration mitigates the decrease of bone quantity and bone quality of leptin receptor-deficient db/db mice by promoting bone formation and inhibiting bone resorption.

Mechanical vibration mitigates the decrease of bone quantity and bone quality of leptin receptor-deficient db/db mice by promoting bone formation and inhibiting bone resorption.

DOI:10.1002/jbmr.2837
发表时间:2016
2

TRAF4, a new substrate of SIAH1, participates in chemotherapy resistance of breast cancer cell by counteracting SIAH1‑mediated downregulation of β‑catenin

TRAF4, a new substrate of SIAH1, participates in chemotherapy resistance of breast cancer cell by counteracting SIAH1‑mediated downregulation of β‑catenin

DOI:
发表时间:2020
3

补肺法治疗慢性阻塞性肺疾病临床研究

补肺法治疗慢性阻塞性肺疾病临床研究

DOI:10.16448/j.cjtcm.2018.0058
发表时间:2018
4

护阳养坤方通过JNK-p38/P65-NF-κB通路对卵巢颗粒细胞的保护机制研究

护阳养坤方通过JNK-p38/P65-NF-κB通路对卵巢颗粒细胞的保护机制研究

DOI:10.3969/j.issn.1008-0805.2022.02.07
发表时间:2022
5

Fatty acid-binding protein 5 aggravates pulmonary artery fibrosis in pulmonary hypertension secondary to left heart disease via activating wnt/β-catenin pathway

Fatty acid-binding protein 5 aggravates pulmonary artery fibrosis in pulmonary hypertension secondary to left heart disease via activating wnt/β-catenin pathway

DOI:https://doi.org/10.1016/j.jare.2021.11.011
发表时间:2021

相似国自然基金

1

δ-catenin通过Kaiso促进肺癌细胞侵袭、转移和增殖的机制研究

批准号:81071717
批准年份:2010
负责人:戴顺东
学科分类:H1809
资助金额:10.00
项目类别:面上项目
2

Wnt5a/Ror2信号通路在卵巢癌侵袭转移中的作用及机制研究

批准号:81101981
批准年份:2011
负责人:毛洪鸾
学科分类:H1809
资助金额:22.00
项目类别:青年科学基金项目
3

借Bcr-Abl Y177磷酸化信号靶向激活caspase 8诱导CML细胞凋亡

批准号:30871102
批准年份:2008
负责人:冯文莉
学科分类:H0809
资助金额:31.00
项目类别:面上项目
4

制备BCR-ABL抗原特异的新型TCR-T细胞靶向杀伤CML细胞

批准号:81802074
批准年份:2018
负责人:高淼
学科分类:H2603
资助金额:21.00
项目类别:青年科学基金项目